Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as ketoconazole, may stop the adrenal glands from making androgens. Lenalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor. Giving ketoconazole and hydrocortisone together with lenalidomide may be an effective treatment for prostate cancer. PURPOSE: This phase II trial is studying how well giving ketoconazole and hydrocortisone together with lenalidomide works in treating patients with prostate cancer that did not respond to hormone therapy.

Key facts

Study ID

NCT00460031

Run by

Case Comprehensive Cancer Center

People needed

34

Starts

2006-09-01

Expected to finish

2010-08-31

Last updated by the study team

2020-07-24

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Lake/University Seidman Cancer Center — Cleveland, Ohio, United States
• University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
• University Suburban Health Center — Cleveland, Ohio, United States
• UHHS Chagrin Highlands Medical Center — Cleveland, Ohio, United States
• UHHS Westlake Medical Center — Cleveland, Ohio, United States
• Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.